AzurRx BioPharma, Inc.
Biotech — researches and develops non-systemic biologics to treat patients with gastrointestinal disorders. Focused on developing its lead drug product candidate, MS1819, a recombinant lipase enzyme that treats exocrine pancreatic insufficiency associated with cystic fibrosis and chronic pancreatitis. AzurRx is headquartered in New York, NY, has scientific operations in Langlade, France, and has clinical operations in Hayward, California.
AzurRx is listed on the NASDAQ under the symbol AZRX.
Learn more at www.azurrx.com